Champions Oncology | 10-Q: FY2026 Q1 Revenue: USD 14 M

Revenue: As of FY2026 Q1, the actual value is USD 14 M.

EPS: As of FY2026 Q1, the actual value is USD -0.03.

EBIT: As of FY2026 Q1, the actual value is USD -527 K.

Segment Revenue

• Oncology Revenue: For the three months ended July 31, 2025, oncology revenue was $13.995 million, a slight decrease from $14.061 million in the same period in 2024, representing a 0.5% decline.

Operational Metrics

• Cost of Oncology Revenue: Increased by 13.1% to $7.995 million for the three months ended July 31, 2025, compared to $7.072 million in the prior year period.
• Research and Development Expenses: Increased by 43.2% to $2.082 million for the three months ended July 31, 2025, from $1.454 million in the same period in 2024.
• Sales and Marketing Expenses: Increased by 10.5% to $1.855 million for the three months ended July 31, 2025, from $1.679 million in the same period in 2024.
• General and Administrative Expenses: Slight increase of 1.7% to $2.570 million for the three months ended July 31, 2025, from $2.527 million in the same period in 2024.
• Net Loss: The company reported a net loss of $466,000 for the three months ended July 31, 2025, compared to a net income of $1.313 million in the same period in 2024.

Cash Flow

• Net Cash Provided by Operating Activities: $600,000 for the three months ended July 31, 2025, compared to $311,000 in the same period in 2024.
• Net Cash Used in Investing Activities: $46,000 for the three months ended July 31, 2025, primarily due to purchases of lab and computer equipment.
• Net Cash Used in Financing Activities: $14,000 for the three months ended July 31, 2025, resulting from financing lease payments partially offset by proceeds from stock options exercises.

Unique Metrics

• TOS Data License Revenue: $311,000 for the three months ended July 31, 2025, with no comparable revenue in the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue leveraging its TumorGraft Technology Platform to facilitate drug discovery and development at lower costs and increased speeds. It aims to expand its data licensing platform and invest in Corellia, its subsidiary focused on target discovery.
• Non-Core Business: The company is evaluating strategic options for its drug discovery business, which may include potential spin-out transactions or capital raises.